Experimental vaccine appears affective in cervical cancer patients

17 Sep 2015

The experimental cancer vaccine of Advaxis was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments.

About 38.5% of the patients in a mid-stage study, whose disease had progressed or returned after prior therapy, survived for a year after being given the Advaxis vaccine, the biotech company announced.

An effective treatment with no serious adverse events

No serious adverse events were reported. However, about 15% of patients experienced hypotension and cytokine release syndrome, and one patient experienced lung infection and sepsis. According to Vernon Bernardino, FBR & Co analyst, the 38.5% survival rate Advaxis reported was higher than the 27% rate its reported from earlier studies.

CareAcross-vial-and-syringe

Positive results from the mid-stage study project Advaxis' lead cancer therapy, axalimogene filolisbac, as a direct competitor to Roche AG's blockbuster treatment Avastin. Advaxis' vaccine was being tested as a standalone treatment for persistent or recurrent metastatic cervical cancer related to the human papilomavirus. The results mirror an earlier study conducted by the company in cervical cancer patients in India.

The therapy is expected to be approved in the United States in late 2017 or early 2018.

Source: Reuters
No Comment